Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2009-11-25
2011-12-20
Landsman, Robert (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C536S023100, C514S016600, C514S017900
Reexamination Certificate
active
08080246
ABSTRACT:
The present invention relates to specific CSF1R ECD fusion molecules that exhibit improved therapeutic properties. The invention also relates to polypeptide and polynucleotide sequences, vectors, host cells, and compositions comprising or encoding such molecules. The invention also relates to methods of making and using the CSF1R ECD fusion molecules. The invention further relates to methods of treatment using the CSF1R ECD fusion molecules. For example, certain CSF1R ECDs of the invention may be used to treat rheumatoid arthritis (RA) or multiple sclerosis (MS).
REFERENCES:
patent: 5866114 (1999-02-01), Pandit et al.
patent: 6184354 (2001-02-01), Koths et al.
patent: 7108852 (2006-09-01), Devalaraja et al.
patent: 7247618 (2007-07-01), Rajavashisth
patent: 7455836 (2008-11-01), Hamilton et al.
patent: 2002/0119494 (2002-08-01), Jung et al.
patent: 2006/0286102 (2006-12-01), Jin et al.
patent: 2007/0148172 (2007-06-01), Lawson et al.
patent: 2007/0166788 (2007-07-01), Jin et al.
patent: 2010/0136006 (2010-06-01), Lin et al.
patent: 2388298 (2001-05-01), None
patent: 2241333 (2010-10-01), None
patent: WO 89/03687 (1989-05-01), None
patent: WO 99/29345 (1999-06-01), None
patent: WO 01/34177 (2001-05-01), None
patent: WO 2004/045532 (2004-06-01), None
patent: WO 2005/070447 (2005-08-01), None
patent: WO 2006/012451 (2006-02-01), None
patent: WO 2007/075933 (2007-07-01), None
patent: WO 2007/081879 (2007-07-01), None
patent: WO 2007/081879 (2007-07-01), None
patent: WO 2007/120252 (2007-10-01), None
patent: WO 2008/060610 (2008-05-01), None
patent: WO 2008/124858 (2008-10-01), None
patent: WO 2008/150383 (2008-12-01), None
patent: WO 2009/026303 (2009-02-01), None
patent: WO 2009/112245 (2009-09-01), None
International Search Report and Written Opinion mailed Jun. 9, 2010, for Application No. PCT/US 09/06299, filed Nov. 25, 2009 (17 pages).
International Search Report and Written Opinion mailed May 24, 2010, for Application No. PCT/US 09/06301, filed Nov. 25, 2009 (13 pages).
Aharinejad et al., Colony-stimulating Factor-1 Blockade by Antisense Oligonucleotides and Small Interfering RNAs Suppresses Growth of Human Mammary Tumor Xenografts in Mice, Cancer Research, vol. 64, Aug. 2004, pp. 5378-5384.
Aharinejad et al., Colony-stimulating Factor-1 Antisense Treatment Suppresses Growth of Human Tumor Xenografts in Mice, Cancer Research, vol. 62, Sep. 2002, pp. 5317-5324.
Ando et al., Imatinib Mesylate Inhibits Osteoclastogenesis and Joint Destruction in Rats with Collagen-induced Arthritis, J. Bone Miner. Metab., vol. 24, Jan. 2006, pp. 274-282.
Apollo Cytokine Research, Human hcx-™ M-CSF R, Fc Chimera, Product Information Sheet from http://www.biocompare.com/itemdetails.asp?itemid=837066, printed Feb. 4, 2008 (2 pages).
Birchenall-Roberts, Inhibition of Murine Monocyte Proliferation by a Colony-stimulating Factor-1 Antisense Oligodeoxynucleotide, J. Immunol., vol. 145, Nov. 1990, pp. 3290-3296.
Bischof et al., Exacerbation of Acute Inflammatory Arthritis by the Colony-stimulating Factors CSF-1 and Granulocyte Macrophage (GM)-CSF: Evidence of Macrophage Infiltration and Local Proliferation, Clin. Exp. Immunol., vol. 119, 2000, pp. 361-367.
Campbell et al., The Colony-stimulating Factors and Collagen-induced Arthritis: Exacerbation of Disease by M-CSF and G-CSF and Requirement for Endogenous M-CSF, J. Leukoc. Biol., vol. 68, Jul. 2000, pp. 144-150.
Chaika et al., CSF-1 Receptor/Insulin Receptor Chimera Permits CSF-1-dependent Differentiation of 3T3-L1 Preadipocytes, J. Biol. Chem., vol. 272, No. 18, May 1997, pp. 11968-11974.
Chitu et al, Colony-stimulating Factor-1 in Immunity and Inflammation, Curr. Opin. Immunol., vol. 18, No. 1, Feb. 2006, pp. 39-48.
Conway et al., Inhibition of Colony-stimulating-factor-1 Signaling in vivo with the Orally Bioavailable cFMS Kinase Inhibitor GW2580, PNAS, vol. 102, No. 44, Nov. 2005, pp. 16078-16083.
Conway et al., Effects of the cFMS Kinase Inhibitor 5-(3-Methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in Normal and Arthritic Rats, J. Pharmacol. Exp. Therapeutics, vol. 326, No. 1, Apr. 2008, pp. 41-50.
Dandekar et al., Comparison of the Signaling Abilities of the Cytoplasmic Domains of the Insulin Receptor and the Insulin Receptor-related Receptor in 3T3-L1 Adipocytes, Endocrinology, vol. 139, No. 8, 1998, pp. 3578-3584.
Dewar et al., Imatinib as a Potential Antiresorptive Therapy for Bone Disease, Blood, vol. 107, No. 11, Jun. 2006, pp. 4334-4337.
Goswami et al., Macrophages Promote the Invasion of Breast Carcinoma Cells via a Colony-stimulating Factor-1/Epidermal Growth Factor Paracrine Loop, Cancer Res., vol. 65, No. 12, Jun. 2005, pp. 5278-5283.
Hamilton, CSF-1 Signal Transduction, J. Leukoc. Biol., vol. 62, Aug. 1997, pp. 145-155.
Hamilton, Colony-stimulating Factors in Inflammation and Autoimmunity, Nature Reviews, vol. 8, Jul. 2008, pp. 533-544.
Hegen et al., Utility of Animal Models for Identification of Potential Therapeutics for Rheumatoid Arthritis, Ann. Rheum. Dis., vol. 67, published online Nov. 2007, pp. 1505-1515.
Ide et al., Expression of Colony-stimulating Factor 1 Receptor During Prostate Development and Prostate Cancer Progression, PNAS, vol. 99, No. 22, Oct. 2002, pp. 14404-14409.
Ide et al., Serum Level of Macrophage Colony-stimulating Factor is Increased in Prostate Cancer Patients with Bone Metastasis, Human Cell, vol. 21, No. 1, Feb. 2008, pp. 1-6.
Irvine et al., A CSF-1 Receptor Kinase Inhibitor Targets Effector Functions and Inhibits Pro-inflammatory Cytokine Production from Murine Macrophage Populations, FASEB, vol. 20, Sep. 2006, pp. E1315-E1326.
Kingsley et al., Molecular Biology of Bone Metastasis, Mol. Cancer Ther., vol. 6, No. 10, Oct. 2007, pp. 2609-2617.
Kitaura et al., M-CSF Mediates TNF-induced Inflammatory Osteolysis, J. Clin. Invest., vol. 115, No. 12, Dec. 2005, pp. 3418-3427.
Kluger et al., Macrophage Colony-stimulating Factor-1 Receptor Expression is Associated with Poor Outcome in Breast Cancer by Large Cohort Tissue Microarray Analysis, Clinical Cancer Res, vol. 10, Jan. 2004, pp. 173-177.
Kubota et al., M-CSF Inhibition Selectively Targets Pathological Angiogenesis and Lymphangiogenesis, J. Exp. Med., vol. 206, No. 5, Apr. 2009, pp. 1089-1102.
Kutza et al., Macrophage Colony-stimulating Factor Antagonists Inhibit Replication of HIV-1 in Human Macrophages, J. Immunol., 2000, vol. 164, pp. 4955-4960.
Lee et al., Functional Dissection of Structural Domains in the Receptor for Colony-stimulating Factor-1, J. Biol. Chem., vol. 267, No. 23, Aug. 1992, pp. 16472-16483.
Li et al., Conditional Deletion of the Colony Stimulating Factor-1 Receptor (c-fmsProto-Oncogene) in Mice, Genesis, vol. 44, May 2006, pp. 328-335.
Li et al., Role of Dimerization and Modification of the CSF-1 Receptor in its Activation and Internalization During the CSF-1 Response, The EMBO Journal, vol. 10, No. 2, 1991, pp. 277-288.
Lin et al., Colony-stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy, J. Exp. Med., vol. 193, No. 6, Mar. 2001, pp. 727-739.
Lin et al., The Macrophage Growth Factor CSF-1 in Mammary Gland Development and Tumor Progression, J. Mammary Gland Biology Neoplasia, vol. 7, Apr. 2002, pp. 147-162.
Lin et al., Discovery of a Cytokine and its Receptor by Functional Screening of the Extracellular Proteome, Science, vol. 320, May 2008, pp. 807-811.
Lin et al., Regulation of Myeloid Growth and Differentiation by a Novel Cytokine, Interleukin-34 (IL-34), via the CSF-1 Receptor, poster presented at Cytokines in Health & Disease, Fifteenth Annual Conference of the International Cytokine Society (San Francisco, CA, Oct. 26-30, 2007, 1 page.
Lipton, Future Treatment of Bone Metastases, Clin Cancer Res, vol. 12, 20 Suppl., Oct. 2006, pp. 6305s-6308s.
Lopez-Diego et al., Novel Therapeutic Strategies for Multiple Sclerosis—A Multifaceted Adversary, Nature Reviews Drug Discovery, vol. 7, Nov. 2008, pp. 909-925.
MacDonald et al., An Antibody Against the Colony-stimulating Factor 1 Receptor Depletes the Resident Subset of Monocytes and Tissue- and Tumor-associated Macrophage
Lin Haishan
Long Li
Dang Ian
Finnegan Henderson Farabow Garrett & Dunner LLP
Five Prime Therapeutics, Inc.
Landsman Robert
LandOfFree
Colony stimulating factor 1 receptor (CSF1R) extracellular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Colony stimulating factor 1 receptor (CSF1R) extracellular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Colony stimulating factor 1 receptor (CSF1R) extracellular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4309784